# A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients

> **NCT00922883** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 43 (actual)

## Conditions studied

- Anemia, Aplastic
- Anemia, Hypoplastic
- Thrombocytopenia

## Interventions

- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT00922883
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-29
- **Primary completion:** 2013-05-07
- **Final completion:** 2018-04-24
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00922883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00922883, "A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00922883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*